Kornimate/medical-research-clean huggingface dataset:
randomized trial of a liberal versus a restrictive transfusion strategy in elderly cardiac surgery patients

Conditions: Anemia; Coronary Artery Bypass Surgery

Summary: the purpose of this study is to determine whether a less restrictive strategy of red blood cell transfusion in elderly patients following coronary bypass surgery results in enhanced postoperative recovery as determined by quality of life assessment, exercise tolerance and clinical outcomes. two postoperative transfusion strategies: 1. liberal - transfused when hgb is \<100g/l 2. restrictive - transfused when hgb is \<70g/l


Eligibility criteria:
inclusion criteria: * patients \>=70 years of age undergoing non-emergency coronary artery bypass surgery * initial postoperative hemoglobin level 70-90g/l exclusion criteria: * patients who are unable to provide informed consent in english * patients with preoperative hemoglobin concentrations \<100g/l * patients who require emergency re-operation * patients with intraoperative or postoperative bleeding diathesis * patients with postoperative clinical instability (eg. low output state) * patients in whom insertion of an intra-aortic balloon pump is required

Keywords: postoperative care cardiac surgery blood transfusion
non-invasive monitor in endoscopic invasive procedure

Conditions: Cholangiopancreatography, Endoscopic Retrograde; Endoscopic Ultrasonography

Summary: investigators include the patients who need painless invasive endoscopic procedure, investigators collect the demographic data and apply the non-invasive device icon on participants during the who procedure.

invasive endoscopy procedure including endoscopic retrograde cholangio-pancreatography (ercp), endoscopic ultrasound guided fine needle aspiration (eus-fna), endoscopic retrograde biliary drainage (erbd) and others is more and more popular which become the standard treatment before surgical intervention. however; the elder group who need this procedure is getting more common. the painless endoscopic sedation for elder group who has more comorbidity is not easy. during the procedure, the investigators found that the anticholinergic medication-buscopam which in order to suppress intestine mobilization can cause obvious tachycardia. tachycardia makes the stroke volume decrease which enhance the perioperative hypotension, and the vasodilation effect of the analgesics make it worse. investigators are trying to find the non-invasive predictor of perioperative hypotension in geriatric group. investigators collected the patients who need painless endoscopic invasive procedure, investigators will record their hemodynamic data including estimated cardiac output (cco)，index of contractility (icon)，nbp，hr，and saturation. investigators also add the evaluation of frailty to evaluate the relationship between frailty and perioperative complications.

Eligibility criteria:
inclusion criteria: * patient who need painless endoscopic invasive procedures * age above 50 y/o exclusion criteria: -
effects of bbt versus diaphragmatic breathing on exercise capacity and quality of life in patients with copd

Conditions: Breathing Technique

Summary: group a will be treated with manual chest physical therapy and buteyko breathing technique group-b will be treated with manual chest physical therapy and diaphragmatic breathing technique. patients will perform the technique 5 times a weeks for 8weeks and treatment evaluation will be done after 8 weeks

a randomized clinical trial will be conducted at gulab devi hospital, lahore through convenience sampling technique on 48 patients which will be allocated through simple random sampling through sealed enveloped into group a and group b. pre-treatment values of patients exercise capacity will be recorded by 6mwt/6mwd- 6 minute walk test/ 6 minutes' walk distance and patients quality of life through st george respiratory questionnaire as primary outcomes while oxygen saturation, heart rate will be measured by pulse oximtery during 6mwt as secondary outcomes. group a will be treated with manual chest physical therapy and buteyko breathing technique group-b will be treated with manual chest physical therapy and diaphragmatic breathing technique. patients will perform the technique 5 times a weeks for 8weeks and treatment evaluation will be done after 8 weeks. data will be analyzed using spss software version 25.after assessing normality of data by shapiro-wilk test , it will be decidedeither parametric or non-parametric test will be used.

Eligibility criteria:
inclusion criteria: * age group : 40-65 years * both males and females * clinical diagnosis of copd confirmed by smoking history and pft airflow * patients taking their regular medications e.g bronchodilator exclusion criteria: * restrictive lung disease * pneumothorax * resting o2 saturation \<90% with room air breathing * recent exacerbations * patients with active viral or bacterial infection * abdominal or thoracic surgery (\<3months ago) * cardiologic conditions (\<6months ago e.g myocardial infarction or unstable angina * intubated patients * orthopedic or urogenital conditions * neurological disorders limiting cognition \& mobility

Keywords: chronic obstructive pulmonary disease/copd diaphragmatic breathing technique
minocycline treatment in acute hemorrhagic stroke

Conditions: Poor Performance Status

Summary: the investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.

minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have a clear beneficial neuroprotective effect in animal models of multiple sclerosis, parkinson's disease, huntington's disease and amyotrophic lateral sclerosis. animal models provide promising evidence of minocycline's ability to improve outcomes in an animal stroke model. in light of these findings, we will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.

Eligibility criteria:
inclusion criteria: * patients with acute hemorrhagic stroke 1. age \> 18 2. nihss score \> 5 3. onset of stroke 6 to 24 hours prior to beginning of treatment. patients, who arrived within 0 to 6 hours post stroke, were treated with other medications according to the best accepted medical treatment guidelines. exclusion criteria: 1. evidence of other disease of the central nervous system, including brain tumor, demyelinating disease, inflammatory disease of the central nervous system, craniotomy in the past, severe brain injuries and benign intracranial hypertension 2. pre-existing neurological disability 3. known allergic response to tetracyclines 4. acute or chronic renal failure 5. pre-existing infectious disease requiring antibiotic therapy 6. swallowing difficulties
aquatic group exercise for people with parkinson disease

Conditions: Parkinson Disease

Summary: this study will investigate the impact of land based or aquatic based group exercise on the balance, walking, balance confidence, and quality of life of people with idiopathic parkinson disease. participants will be randomized to participate in a land based or aquatic based group exercise program 2 times per week for 12 weeks. prior to and after participation, balance, walking, quality of life, and balance confidence will be measured by a blinded examiner.


Eligibility criteria:
inclusion criteria: * adults over the age of 18 who have been diagnosed with idiopathic parkinson disease. * stable dose of levadopa medication for 30 days prior to study initiation * able to walk 20 feet without physical assistance * a referral from a physician to participate in physical therapy exclusion criteria: individuals with: * uncontrolled cardiovascular or pulmonary conditions * deep vein thrombosis in the last 6 months * the use of breathing tube or feeding tube * those with an extreme fear of exercising in the water * an active dermatological condition (including eczema, psoriasis, or open wound) -any other neurological condition other than parkinson disease * a musculoskeletal condition that would impact their ability to participate in the exercise group * cognitive impairment (a score of less than 24/30 on the mini mental status examination)
safety and efficacy of a new treatment in vitrectomized subjects with diabetic macular edema

Conditions: Diabetic Macular Edema; Vitrectomy

Summary: the study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. subjects will be followed for 26 weeks.


Eligibility criteria:
inclusion criteria: * 18 years of age or older with diabetic macular edema * history of vitrectomy * central retinal thickness ≥ 275 µm * visual acuity between 20/320 and 20/40 in the study eye and no worse than 20/200 in the other eye exclusion criteria: * known anticipated need for ocular surgery during the study period * history of glaucoma or current high eye pressure requiring more than 1 medication * uncontrolled systemic disease * known allergy to the study medication * known steroid-responder * use of systemic steroids * female subjects that are pregnant, nursing or planning a pregnancy
bioactive microstructured anti microbial precoated surface implant versus non-coated surface implant in type 2 diabetic patients in the mandible

Conditions: Dental Implant; Diabetes Mellitus, Type 2

Summary: dental implant's surface properties significantly influence both biological and mechanical integration. surface bio-treatment could accelerate and enhance bone regeneration, ensuring successful implantation. therefore, this study compares bone densification, primary and secondary stability, wound healing, and pain intensity between pre-coated antimicrobial surfaces of dental implants versus non-coated surfaces in controlled type 2 diabetic patients.


Eligibility criteria:
inclusion criteria: * adequate interproximal space. * adequate interocclusal space. * adequate anatomical location, accessibility, and visualization for easy surgical implant placement. * both genders. * controlled medical condition exclusion criteria: * presence of parafunctional dependency as bruxism. * adjacent pathosis near the implant site. * patient under radiotherapy targeting the head and neck. * heavy smokers.
temozolomide in treating patients with recurrent glioblastoma multiforme or other malignant glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. purpose: this phase ii trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.

objectives: primary * determine the progression-free survival rate at 6 months in patients with recurrent glioblastoma multiforme or other malignant glioma treated with temozolomide. secondary * determine the overall survival of patients treated with this drug. outline: patients receive oral temozolomide once daily in the absence of disease progression or unacceptable toxicity. blood samples are collected at baseline and every 2 months for 2 years for evaluation of markers of neo-angiogenesis. samples are analyzed by protein expression, reverse-transcriptase pcr, elisa, and western blot. (samples are no longer being collected and tested as of 1/12/09)

Eligibility criteria:
disease characteristics: * pathologically diagnosed glioblastoma multiforme or other malignant glioma * recurrent disease * must have received prior temozolomide patient characteristics: * karnofsky performance status 60-100% * granulocyte count ≥ 1,500/mm³ * platelet count ≥ 100,000/mm³ * sgot ≤ 2.5 times upper limit of normal (uln) * creatinine ≤ 2 times uln * bilirubin ≤ 2 times uln * no other active malignancy except for cervical carcinoma in situ or basal cell carcinoma of the skin * no serious medical or psychiatric illness that, in the opinion of the investigator, would preclude study treatment * no medical condition that precludes swallowing pills * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: * see disease characteristics * recovered from all prior therapy

Keywords: recurrent adult brain tumor adult giant cell glioblastoma adult glioblastoma adult gliosarcoma adult anaplastic astrocytoma adult diffuse astrocytoma adult pilocytic astrocytoma adult subependymal giant cell astrocytoma adult anaplastic ependymoma adult ependymoma adult myxopapillary ependymoma adult subependymoma adult anaplastic oligodendroglioma adult oligodendroglioma adult brain stem glioma adult mixed glioma adult pineal gland astrocytoma
set point acupuncture for migraines using a digital assistant

Conditions: Migraine Headaches

Summary: the object of this research study is to test a standardized set of acupuncture points on migraine patients to reduce frequency and intensity of headaches. acupuncture has been studied in prior research but the treatment points have varied between subjects, making it difficult to replicate studies.

subjects will be recording daily headache activity on personal digital assistants (pda's) for 12 weeks before and 12 weeks after 8 weeks of acupuncture intervention. midas, hit-6 and bdi-ii measurements will be done at the beginning of the study (12 weeks pre-intervention), directly before the intervention, directly after, and 12 weeks post-intervention. measurements will be compared before and after intervention. this is a follow-up to a successful earlier study when these same acupuncture points were used on subjects with chronic daily headache, the majority being migraine.

Eligibility criteria:
inclusion criteria: * male and female subjects between the ages of 21 years and 65 years of age * subjects with a history of migraine headaches for at least 12 months * subjects who have not received acupuncture for any medical condition in the past 6 months. * a negative pregnancy test for childbearing females since some acupuncture points may be contraindicated in pregnancy. pregnancy tests will be conducted at mmc. * subjects willing and able to use a pda daily for data collection exclusion criteria: * subjects who plan to receive acupuncture treatment for any other type of medical condition while enrolled in this protocol * subjects with the presence of organic pathology (i.e., brain tumor) * subjects who have the presence of a systemic disorder or illness, including serious psychiatric illness * subjects who began a new headache treatment less than two weeks before proposed enrollment date * subjects who are pregnant, lactating, or planning to become pregnant within 6 months * subjects that use alcohol on a regular basis * subjects that use recreational drugs * subjects that have a cardiac pacemaker * subjects that use analgesics on more than 10 days per month * subjects that exercise prophylactic headache treatment with drugs during the past 4 weeks

Keywords: migraine headache acupuncture
phenylephrine versus eyelid taping for muller's muscle-conjunctival resection (mmcr) evaluation

Conditions: Ptosis, Eyelid

Summary: this research study aims to compare whether phenylephrine 2.5% ophthalmic eye drop solution can serve as a better indicator of the effect of a drooping upper eyelid (ptosis) by covering part of the upper portion of the field of vision as compared to traditional use of tape to lift up the upper eyelid in the evaluation of patients for surgical upper eyelid repair.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with ptosis undergoing conjunctival muller's muscle resection evaluation. * individuals who can tolerate and have no hypersensitivity to phenylephrine 2.5% ophthalmic solution. * individuals who can tolerate eye-drop medications. * individuals who are physically able to take a tangent screen visual field test. * age: adults who can comprehend the instructions and procedures (18+ years old) exclusion criteria: - this study will not incorporate any of the following at-risk populations: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners. * this study will not include participants who refuse to consent. * this study will not include participants who are too tired or unable to take a tangent screen visual field test (see risk to subjects). * this study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution. * specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease * this study will not include individuals who consume drugs contraindicated in phenylephrine use: ergot derivatives (vasoconstrictive cyp3a4 substrates), iobenguane radiopharmaceutical products, kratom, lisuride, monoamine oxidase inhibitors
ultrasound guyded venous puncture for safe af ablation procedures

Conditions: Puncture for Safe Atrial Fibrillation Ablation

Summary: to assess if ultrasound guided venous puncture reduces the risk for access site complication in the contex of atrial fibrillation ablation.


Eligibility criteria:
inclusion criteria: * inclusion criteria 1. age ≥18 years 2. signed written informed consent 3. planned transvenous catheter ablation procedure for af or left atrial tachycardia 4. willingness to participate in follow-up exclusion criteria 1. patient is unable or unwilling to provide informed consent 2. planned/required arterial access (e.g. for blood pressure monitoring) 3. patient has contra-indication to oral anticoagulation 4. known coagulation disorder or thrombocytopenia \<150.000/ul. 6. women currently pregnant or breastfeeding or women of childbearing potential without highly effective contraception (pearl-index \< 1%), 7. patient is included in another clinical trial 8. inability to comply with the study procedures
a study to confirm the efficacy and safety of k-161 ophthalmic solution for treatment of moderate to severe dry eye disease

Conditions: Dry Eye Disease

Summary: the purpose of this study is to assess the efficacy and safety of k-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age at the time of informed consent * have a reported history of dry eye disease in both eyes and a history of eye drop use for dry eye symptom * meet all other inclusion criteria outlined in the clinical study protocol exclusion criteria: * have any clinically significant ocular condition * have a history of corneal refractive surgery and/or any other ocular surgical procedure within 12 months * meet any other exclusion criteria outlined in the clinical study protocol
intraocular pressure after preserflo / innfocus microshunt implantation vs trabeculectomy

Conditions: Primary Open Angle Glaucoma; Pseudoexfoliation Glaucoma

Summary: the aim of this project is to compare trabeculectomy with preserflo / innfocus microshunt in patients with primary angle open glaucoma and pseudoexfoliation glaucoma regarding the reduction of intraocular pressure.

the study is a prospective, randomized, monocentric, part blinded, controlled non-inferiority study of glaucoma patients.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * primary open angle glaucoma or pseudoexfoliation glaucoma * medically uncontrollable intraocular pressure or intolerance of topical therapy * negative urine/serum pregnancy test of women in childbearing age * signed and dated informed consent exclusion criteria: * previous incisional glaucoma procedure on affected eye * pregnancy, nursing period * patients in military service, training periods and civil service * participation in another clinical trail * pre-existing ocular pathologies: high myopia (refraction ≥8.00 d), thin conjunctiva
left atrial thrombus on transesophageal echocardiography

Conditions: Atrial Fibrillation; Atrial Flutter; Transesophageal Echocardiography; Ablation; Cardioversion; Thrombus; Embolism

Summary: the aim of the study is to assess the prevalence of left atrial thrombus in patients with atrial fibrillation (af) or atrial flutter (afi), in whom transesophageal echocardiography is performed before af/afl cardioversion or ablation.

atrial fibrillation (af) and atrial flutter (afi) increase the risk of thromboembolic events by promoting clot formation in the left atrium (la). transesophageal echocardiography (tee) is routinely used to exclude the presence of an la thrombus before af/afi ablation or cardioversion. so far, it has not been established what is the optimal combination of noninvasive parameters for thromboembolic risk stratification in this setting. the present study is aimed to compare the prevalence of la thrombus in patients on different anticoagulant regimens, identify predictors of la thrombus and validate the newly developed cha2ds2-vasc-af-gfr score (and to compare its predictive value in la thrombus identification with those of the cha2ds2-vasc and the chads2 scores). the study protocol all patients with af or afl in whom tee will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.

Eligibility criteria:
inclusion criteria: * all patients with af or afl in whom tee will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.

Keywords: atrial fibrillation atrial flutter transesophageal echocardiography ablation cardioversion thrombus; embolism
a study to assess immunogenicity parameters after vaccination against influenza and to evaluate how these parameters change during the influenza season

Conditions: Influenza

Summary: a study to evaluate the humoral immune response 3 weeks after vaccination with inflexal v according to the chmp criteria in elderly subjects for the 2011/2012 who recommended vaccine strains, to evaluate immunogenicity parameters 6 months after vaccination for the 3 vaccine strains and to assess the cross-protection against 4 selected circulating heterogeneous a/h1n1 influenza strains 3 weeks after influenza vaccination versus baseline.


Eligibility criteria:
inclusion criteria: * healthy female and male adults aged \>60 years on the day of enrollment * written informed consent * females with confirmed menopause (postmenopausal is defined as 12 months with no menses without an alternative medical cause) exclusion criteria: * acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * acute febrile illness (≥38.0 °c) * prior vaccination with an influenza vaccine for season 2011/2012 * known hypersensitivity to any vaccine component * previous history of a serious adverse reaction to influenza vaccine * history of egg protein allergy or severe atopy * known blood coagulation disorder * chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, including oral corticosteroids in dosages of ≥0.5 mg/kg/day prednisolone or equivalent (inhaled or topical steroids are allowed) * known immunodeficiency (including leukemia, hiv seropositivity) or cancer * investigational medicinal product received in the past 3 months (90 days) * treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days) * participation in another clinical trial * employee at the investigational site or relative of the investigator * anticipated non-compliance with study procedures

Keywords: influenza virus vaccination immunisation